Vibegron: 9 agencies, 2024–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where vibegron met resistance it was usually narrowed rather than refused: 3 of 8 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Every record falls within a 1.7-year window, 2 Aug 2024 to 2 Apr 2026 — a compressed review cycle.
CIPM (Spain) changed its position: recommended on 24 Apr 2025, not recommended by 24 Apr 2025.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 10 of 10 records date from 2023 or later.
3 distinct indication wordings are recorded for vibegron by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess vibegron, on 2 Aug 2024; HIRA (South Korea) did not open a file until 2 Apr 2026 — a moderate spread of 1.7 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 10 dated records fall in 2025 alone.
Restriction is doing real work here: 3 of 8 decisive outcomes narrowed vibegron to a subgroup rather than accepting or refusing it outright, at HIRA (South Korea), NICE (England) and TLV (Sweden).
CIPM (Spain) is the only agency to have returned to vibegron, recording 2 separate entries.
9 of the 18 agencies in this archive hold a record for vibegron.
The full ledger for vibegron reads 4 recommended, 3 restricted, 1 no benefit and 1 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 21 Aug 2025 | Obgemsa — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 23 Jul 2025 | Listing (Transparency Committee) | SMR low · ASMR V | source |
| ZIN (Netherlands) | 30 Apr 2025 | Advies - vergoed vibegron (Obgemsa®) voor de behandeling van een overactieve blaas | reimbursed | source |
| CIPM (Spain) | 24 Apr 2025 | Indicación terapéutica autorizada: Tratamiento sintomático de pacientes adultos con síndrome de vejiga hiperactiva (VH).… | not financed by the SNS | source |
| TLV (Sweden) | 21 Feb 2025 | Obgemsa ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
5 further decisions for vibegron, across 5 agencies, are not shown here. They include the most recent record on file, 2 Apr 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 4 further source documents.
Related molecules
- sildenafil — same ATC class G04B — Urologicals
- tadalafil — same ATC class G04B — Urologicals
- mirabegron — same ATC class G04B — Urologicals
- apomorphine — same ATC class G04B — Urologicals
- solifenacin — same ATC class G04B — Urologicals
- oxybutynin — same ATC class G04B — Urologicals
Coverage: 10 decisions for vibegron from 9 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class G04B — Urologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.